ALK and neoplasm: Only a proportion of PTCL, NOS cases expressed pSTAT3-Y705 (5/34, 15%) and pSTAT3-S727 (16/34, 47%) in more than 70% tumor cells (p<0.001 compared to ALK+ and ALK- ALCL, Figures 2A, B).